DLL3
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9NYJ7-1 |
---|---|
Species | Human |
Sequence | Ala27-Arg490 |
Purity | > 95% as determined by Bis-Tris PAGE |
Endotoxin Level | Less than 1 EU per µg by the LAL method. |
Biological Activity | Immobilized DLL3, His, Human (Cat.No.: Z03813) at 0.1 µg/ml can bind Anti-DLL3 Antibody. |
Expression System | HEK293 |
Theoretical Molecular Weight | 50.4 kDa |
Formulation | Lyophilized from 0.22 µm filtered solution in PBS, 200 mM Arginine, pH 7.4. |
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability | Upon receiving, the lyophilized product remains stable up to 6 months at -20 °C or below as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Target Background | DLL3, a transmembrane protein in the Delta/Serrate/Lag-2 (DSL) family of Notch ligands, inhibits primary neurogenesis and helps divert neurons along specific differentiation pathways. It also contributes to the formation of somite boundaries during paraxial mesoderm segmentation. |
---|

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.